| Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma OL Chinot, W Wick, W Mason, R Henriksson, F Saran, R Nishikawa, ... New England Journal of Medicine 370 (8), 709-722, 2014 | 2802 | 2014 |
| EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood M Weller, M van den Bent, M Preusser, E Le Rhun, JC Tonn, G Minniti, ... Nature reviews Clinical oncology 18 (3), 170-186, 2021 | 1516 | 2021 |
| Short-course radiation plus temozolomide in elderly patients with glioblastoma JR Perry, N Laperriere, CJ O’Callaghan, AA Brandes, J Menten, C Phillips, ... New England Journal of Medicine 376 (11), 1027-1037, 2017 | 1156 | 2017 |
| European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas M Weller, M Van Den Bent, JC Tonn, R Stupp, M Preusser, ... The lancet oncology 18 (6), e315-e329, 2017 | 1086 | 2017 |
| Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook J Garcia, HI Hurwitz, AB Sandler, D Miles, RL Coleman, R Deurloo, ... Cancer treatment reviews 86, 102017, 2020 | 994 | 2020 |
| Radiotherapy for glioblastoma in the elderly F Keime-Guibert, O Chinot, L Taillandier, S Cartalat-Carel, M Frenay, ... New england journal of medicine 356 (15), 1527-1535, 2007 | 957 | 2007 |
| EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma M Weller, M Van Den Bent, K Hopkins, JC Tonn, R Stupp, A Falini, ... The lancet oncology 15 (9), e395-e403, 2014 | 842 | 2014 |
| Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study BG Baumert, ME Hegi, MJ van den Bent, A von Deimling, T Gorlia, ... The Lancet Oncology 17 (11), 1521-1532, 2016 | 531 | 2016 |
| Recent trends in epidemiology of brain metastases: an overview E Tabouret, O Chinot, P Metellus, A Tallet, P Viens, A Goncalves Anticancer research 32 (11), 4655-4662, 2012 | 448 | 2012 |
| Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3 … MJ van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, ... The Lancet 390 (10103), 1645-1653, 2017 | 408 | 2017 |
| Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of … T Sandmann, R Bourgon, J Garcia, C Li, T Cloughesy, OL Chinot, W Wick, ... Journal of clinical oncology 33 (25), 2735-2744, 2015 | 336 | 2015 |
| Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis P Metellus, B Coulibaly, C Colin, AM de Paula, A Vasiljevic, D Taieb, ... Acta neuropathologica 120, 719-729, 2010 | 329 | 2010 |
| Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor … MJ Van den Bent, MJB Taphoorn, AA Brandes, J Menten, R Stupp, ... Journal of clinical oncology 21 (13), 2525-2528, 2003 | 313 | 2003 |
| Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas A Gonzalez-Aguilar, A Idbaih, B Boisselier, N Habbita, M Rossetto, ... Clinical cancer research 18 (19), 5203-5211, 2012 | 279 | 2012 |
| Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research … K Hoang-Xuan, L Taillandier, O Chinot, P Soubeyran, U Bogdhan, ... Journal of clinical oncology 21 (14), 2726-2731, 2003 | 275 | 2003 |
| Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 … MJ van den Bent, CMS Tesileanu, W Wick, M Sanson, AA Brandes, ... The Lancet Oncology 22 (6), 813-823, 2021 | 272 | 2021 |
| A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma AA Brandes, AF Carpentier, S Kesari, JM Sepulveda-Sanchez, ... Neuro-oncology 18 (8), 1146-1156, 2016 | 264 | 2016 |
| Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant … OL Chinot, M Barrie, S Fuentes, N Eudes, S Lancelot, P Metellus, ... Journal of Clinical Oncology 25 (12), 1470-1475, 2007 | 264 | 2007 |
| Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire M Van Leeuwen, O Husson, P Alberti, JI Arraras, OL Chinot, A Costantini, ... Health and quality of life outcomes 16, 1-15, 2018 | 258 | 2018 |
| Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and … V Quillien, A Lavenu, L Karayan‐Tapon, C Carpentier, M Labussière, ... Cancer 118 (17), 4201-4211, 2012 | 251 | 2012 |
